Jeff Yass’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.76M Sell
88,100
-5,600
-6% -$581K ﹤0.01% 3711
2026
Q2
$9.13M Buy
93,700
+28,200
+43% +$2.46M ﹤0.01% 3542
2026
Q1
$5.5M Buy
65,500
+46,100
+238% +$2.67M ﹤0.01% 4071
2025
Q4
$799K Sell
19,400
-122,800
-86% -$4.76M ﹤0.01% 7681
2025
Q3
$5.6M Buy
142,200
+111,000
+356% +$2.84M ﹤0.01% 3893
2025
Q2
$581K Buy
+31,200
New +$585K ﹤0.01% 8822
2021
Q2
– Sell
-1,700
Closed -$322K – 12672
2021
Q1
$322K Buy
+1,700
New +$286K ﹤0.01% 10453

Other funds holding DNTH

Jeff Yass's DNTH Position: Q3 2026 in Review

Jeff Yass increased its Dianthus Therapeutics (DNTH) stake by 181% in Q3 2026, buying an estimated $5.67M and bringing the position to 84,861 shares worth $7.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3775.

Jeff Yass first reported a position in DNTH in Q3 2019 and has held it in 19 quarters since. 273 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Jeff Yass held 84,861 shares of Dianthus Therapeutics worth $7.47M as of Q3 2026.
  • Jeff Yass bought 54,624 Dianthus Therapeutics shares in Q3 2026, an estimated $5.67M.
  • Dianthus Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #3775 holding.
  • Jeff Yass first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 19 quarters since.
  • 273 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.